Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	75362
Country	Brazil

Received	2022-02-12 02:23
Peer-Review Started	2022-02-12 02:26
To Make the First Decision
Return for Revision	2022-04-17 07:52
Revised	2022-04-30 15:09
Second Decision	2022-06-29 03:16
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-07-06 14:56
Articles in Press	2022-07-06 14:56
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-06-25 20:13
Typeset the Manuscript	2022-07-26 00:31
Publish the Manuscript Online	2022-08-10 13:14

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Immunotherapy in biliary tract cancers: Current evidence and future perspectives
Manuscript Source	Invited Manuscript
All Author List	Pedro Luiz Serrano Uson Junior and Raphael LC Araujo
ORCID	Author(s) ORCID Number Pedro Luiz Serrano Uson Junior http://orcid.org/0000-0001-6122-1374 Raphael LC Araujo http://orcid.org/0000-0002-7834-5944
Funding Agency and Grant Number
Corresponding Author	Raphael LC Araujo, MD, PhD, Adjunct Professor, Surgical Oncologist, Department of Surgery, Universidade Federal de São Paulo, Rua Napoleão de Barros, 715, São Paulo 04039-002, Brazil. raphael.l.c.araujo@gmail.com
Key Words	Biliary tract cancer; Cholangiocarcinoma; Anti-programmed cell death protein-1; Anti-programmed death ligand-1; Microsatellite instability high; Tumor mutational burden high
Core Tip	Chemotherapy remains the main treatment for advanced bile duct tumors regardless of tumor aggressiveness and poor overall survival rates. The Food and Drug Administration has approved immune checkpoint inhibitors for agnostic tumors based on biomarkers such as microsatellite instability-high and tumor mutation burden-high. They are important steps in combined treatment with systemic chemotherapy for patients with advanced disease and show encouraging results.
Publish Date	2022-08-10 13:14
Citation	Uson Junior PLS, Araujo RLC. Immunotherapy in biliary tract cancers: Current evidence and future perspectives. World J Gastrointest Oncol 2022; 14(8): 1446-1455
URL	https://www.wjgnet.com/1948-5204/full/v14/i8/1446.htm
DOI	https://dx.doi.org/10.4251/wjgo.v14.i8.1446

Full Article (PDF)	WJGO-14-1446.pdf
Full Article (Word)	WJGO-14-1446.docx
Manuscript File	75362_Auto_Edited-LM.docx
Answering Reviewers	75362-Answering reviewers.pdf
Audio Core Tip	75362-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	75362-Conflict-of-interest statement.pdf
Copyright License Agreement	75362-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	75362-Language certificate.pdf
Peer-review Report	75362-Peer-review(s).pdf
Scientific Misconduct Check	75362-CrossCheck.png
Scientific Misconduct Check	75362-Bing-Gong ZM-2.jpg
Scientific Editor Work List	75362-Scientific editor work list.pdf
CrossCheck Report	75362-CrossCheck report.pdf